Navidea Biopharmaceuticals (NAVB) is getting hammered after hours as the FDA rejects the New Drug Application for its Lymphoseek injection. In the rejection letter, the FDA noted the decision was focused on issues with third-party Lymphoseek contract manufacturing, and was not related to any efficacy or safety data filed within the drug's application. Shares -37% AH.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs